No Data
No Data
Life Sciences Stocks Fall on NIH Funding Concerns
10x Genomics: Strong Revenue Recovery and Promising Growth Opportunities Support Buy Rating
A Quick Look at Today's Ratings for 10x Genomics(TXG.US), With a Forecast Between $18 to $28
Morgan Stanley Maintains Overweight on 10x Genomics, Lowers Price Target to $28
10x Genomics Analyst Ratings
10X Genomics Shares Rise on Q4 Sales Beat